140674-76-6
Chemical Structure
AG957
Synonym(s): Tyrphostin AG957; NSC 654705
- CAS No.: 140674-76-6
- Formula:C15H15NO4
- Molecular Weight:273.28
IUPAC Name: methyl 4-((2,5-dihydroxybenzyl)amino)benzoate
InChIKey: QSFREBZMBNRGOK-UHFFFAOYSA-N
SMILES: OC1=C(C=C(C=C1)O)CNC2=CC=C(C=C2)C(OC)=O
Biological Activity: AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity[1][2]. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AG957 | 99.30% | AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AG957 (Standard) | ≥98% | AG957 (Standard) is the analytical standard of AG957. This product is intended for research and analytical applications. AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity. AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. G Kaur, et al. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994 Apr;5(2):213-22. [Content Brief]
- [2]. R Bhatia, et al. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia. 1998 Nov;12(1 [Content Brief]
- [3]. P A Svingen, et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res. 2000 Jan;6(1):237-49. [Content Brief]
Keywords